NCT06885359

Brief Summary

Study design: monocentric, retrospective, observational and post-market clinical study. Purpose: To demonstrate the safety and performance of CoCrMo LOCK bipolar femoral heads. The eligible study population is represented by the entire population that underwent a hip replacement with CoCrMo LOCK bipolar femoral heads from 1st January 2023 onwards at the site in accordance with the indication for use of the product.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
32mo left

Started Oct 2025

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress19%
Oct 2025Dec 2028

First Submitted

Initial submission to the registry

March 11, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 20, 2025

Completed
7 months until next milestone

Study Start

First participant enrolled

October 1, 2025

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Last Updated

March 26, 2025

Status Verified

March 1, 2025

Enrollment Period

3.2 years

First QC Date

March 11, 2025

Last Update Submit

March 24, 2025

Conditions

Keywords

Femoral headPartial Hip Arthroplasty

Outcome Measures

Primary Outcomes (1)

  • Evaluation of the revision rate of CoCrMo LOCK Bipolar femoral heads at 24 months after surgery.

    At 24 months after intraoperative visit

Secondary Outcomes (8)

  • Evaluation of the dislocation rate (including close reduction) in subjects with CoCrMo LOCK Bipolar femoral heads at 24 months after bipolar hemiarthroplasty

    At 24 months after intraoperative visit

  • Evaluation of the revision incidence of any hip component for any reason at 24 months after bipolar hemiarthroplasty.

    At 24 months after intraoperative visit

  • Evaluation of acetabular erosion (according to Baker classification) in subjects with CoCrMo LOCK Bipolar femoral heads at 12 months after Bipolar Hemiarthroplasty.

    At 12 months after intraoperative visit

  • Assessment of Harris Hip Score (HHS) at 24 months after Bipolar Hemiarthroplasty with CoCrMo LOCK Bipolar femoral heads.

    At 24 months after intraoperative visit

  • Assessment of Oxford Hip Score (OHS) completed by subjects with CoCrMo LOCK Bipolar femoral heads at 24 months after Bipolar Hemiarthroplasty.

    At 24 months after intraoperative visit

  • +3 more secondary outcomes

Study Arms (1)

CoCrMo LOCK bipolar femoral head implanted patient

Patients who underwent hip arthroplasty with CoCrMo LOCK bipolar femoral heads from 1at January 2023 onwards.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients who underwent partial hip arthroplasty with CoCrMo LOCK bipolar femoral heads from 1st January 2023 onwards

You may qualify if:

  • Displaced intracapsular hip fracture (Garden III-IV).
  • Subjects underwent a Bipolar Hemiarthroplasty with a CoCrMo LOCK Bipolar femoral head as per their Indication For Use from January 1st, 2023, onwards.
  • No concurrent joint disease at the time of the surgery.
  • Absence of severe cognitive dysfunction demonstrated by 3 or more correct answers on the Pfeiffer test.
  • Ability to ambulate independently with or without walking aids before surgery.
  • Subject willingness to participate.

You may not qualify if:

  • Undisplaced or minimally displaced intracapsular hip fracture (Garden I-II).
  • Any CoCrMo LOCK Bipolar femoral head contraindication for use as reported in the current Instruction For Use.
  • Pathological fracture secondary to malignant disease.
  • Subjects with rheumatoid arthritis or symptomatic osteoarthritis.
  • Previous treatment to the same hip for a fracture at the time of the surgery.
  • Subjects who were deemed unsuitable for the surgical procedures by the anesthesiologist.
  • Severe cognitive dysfunction or cognitive impairment demonstrated by 2 or less correct answers on the Pfeiffer test.
  • Unable to walk before surgery (e.g., wheelchair or bed-ridden subjects).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Splošna bolnišnica Celje

Celje, 3000, Slovenia

Location

MeSH Terms

Conditions

Femoral Fractures

Condition Hierarchy (Ancestors)

Fractures, BoneWounds and InjuriesLeg Injuries

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 11, 2025

First Posted

March 20, 2025

Study Start

October 1, 2025

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2028

Last Updated

March 26, 2025

Record last verified: 2025-03

Locations